期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新辅助化疗对乳腺癌雌、孕激素受体及HER-2的影响 被引量：3

下载PDF
导出
摘要 目的探讨新辅助化疗对乳腺癌雌、孕激素受体(ER、PR)及HER-2表达的影响。方法 65例接受新辅助化疗的乳腺癌患者纳入研究,分析患者术前弹射式空芯针穿刺活检标本和术后大标本癌组织ER、PR和HER-2表达的变化。结果新辅助化疗前ER阳性表达率46.15%(30/65),化疗后ER阳性表达率50.8%(33/65)差异无统计学意义(χ2=0.364,P>0.05)。新辅助化疗前PR阳性表达率43.1%(28/65),化疗后PR阳性表达率36.9%(24/65),差异无统计学意义(χ2=1.125,P>0.05)。新辅助化疗前HER-2阳性表达率40%(26/65),化疗后HER-2阳性表达率44.6%(29/65),差异无统计学意义(2=0.364,P>0.05)。结论新辅助化疗对乳腺癌ER、PR及HER-2的表达无影响。
作者 徐飚 张晓清 刘鹏熙 陈前军 任黎萍
机构地区 广东省中医院乳腺科 广州中医药大学
出处 《广东医学》 CAS CSCD 北大核心 2010年第11期1423-1425,共3页 Guangdong Medical Journal
关键词 乳腺肿瘤 新辅助化疗 激素受体
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1ARENS N,BLEYL U,HILDENBRAND R.HER2/neu,p53,Ki67,and hormone receptors do not change during neoadjuvant chemotherapy[J].Virchows Arch,2005,44(6):489-496.
  • 2BURSTEIN H J,HARRIS L N,GELMAN R,et al.Preoperative therapy with Trastuzumab and Paclitaxel followed by sequential adjuvant Doxorubicin/Cyclophosphamide for HER2 overexpressing stage II or III breast cancer:a pilot study[J].J Clin Oncol,2003,21(1):46-53.
  • 3KASAMI M,UEMATSU T,HONDA M,et al.Comparison of estrogen receptor,progesterone receptor and Her-2 status in breast cancer pre-and post-neoadjuvant chemotherapy[J].Breast,2008,17(5):523-527.
  • 4TAUCHER S,RUDAS M,GNANT M.Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy[J].Endocr Relat Cancer,2003,10(1):91-98.
  • 5赵健,吴一龙,王远东,赵光日,王建.新辅助化疗对乳腺癌雌、孕激素受体和HER-2的影响[J].第一军医大学学报,2004,24(12):1437-1439. 被引量：9
  • 6包刚,杨德启,周波,刘鹏,王殊,程琳.新辅助化疗对乳腺癌组织中雌激素、孕激素受体及P53和CerbB-2表达的影响[J].中华医学杂志,2007,87(40):2843-2845. 被引量：36
  • 7GREGORY R K,POWELS T J,SALTER J,et al.Prognostic relavance of CerbB-2 expression following neoadjuvant chemotherapy in patients in a randomized trial of neoadjuvant versus adjuvant chemoendocrinetherapy[J].Breast Cancer Res Treat,2000,59(2):171-l75.
  • 8LEE S H,CHUNG M A,QUDDUS M R.The effect of neoadjuvant chemotherapyon estrogen and progesterone receptor expression an hormonal receptorstatus in breast cancer[J].Am J Surg,2003,186(4):345-350.
  • 9张震寰,吴凯南,汪康莹,刘胜春.术前化疗对晚期乳腺癌雌激素受体含量的影响[J].中国肿瘤临床,2001,28(12):895-897. 被引量：11
  • 10MARTIN M B,ANGELONI S V,GARCIA MORALES P,et al.Regulation of estrogen receptor-alpha expression inMCF-7 cells by taxol[J].J Endocrinol,2004,180(3):487-496.

二级参考文献31

  • 1傅以凡 吴凯南 等.应用MCG法检测乳腺癌雌激素受体的初步报告[J].中华肿瘤杂志,1992,14(2):158-158.
  • 2Lo S S，J Surg Oncol，1994年，57卷，2期，94页
  • 3傅以凡，中华肿瘤杂志，1992年，14卷，2期，158页
  • 4Fromowitz FB, Viola MV, Chao S, et al. Ras p21expression in the progression of breast cancer [J]. Hum Pathol, 1987,18:1268-1273.
  • 5Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. Clin Oncol,2003,21:4165-4174.
  • 6Buchholz TA, Stivers DN, Stec J. et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer [ J ]. Cancer J, 2002,8: 461-468.
  • 7Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma[J]. Am Surg, 1996,62:162-165.
  • 8Makris A, Powles TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study [J].Breast Cancer Res Treat, 1999,53: 51-59.
  • 9Schneider J, Lucas R, Sanchez J, et al. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDRI and LRP [ J ]. Anticancer Res, 2000,20:4373-4377.
  • 10Lee SH, Chung MA, Quddus MR. The effect of neoadjuvantchemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer[J]. Am J Surg,2003,186:348-350.

共引文献64

同被引文献16

  • 1赵波涛,罗庆丰,高玟,黄传生,涂侃.新辅助化疗对乳腺癌激素受体ER、PR表达的影响[J].实用癌症杂志,2014,29(1):8-9. 被引量：7
  • 2赵健,吴一龙,王远东,赵光日,王建.新辅助化疗对乳腺癌雌、孕激素受体和HER-2的影响[J].第一军医大学学报,2004,24(12):1437-1439. 被引量：9
  • 3包刚,杨德启,周波,刘鹏,王殊,程琳.新辅助化疗对乳腺癌组织中雌激素、孕激素受体及P53和CerbB-2表达的影响[J].中华医学杂志,2007,87(40):2843-2845. 被引量：36
  • 4Dowsett M, Dunbier AK. Emerging biomarkers and new under- standing of traditional markers in personalized therapy for breast cancer[J]. Clin Cancer Res, 2008,14(24) : 8019-8026.
  • 5Kasami M, Uematsu T, Honda M, et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy[J]. Breast, 2008,17(5) : 523-527.
  • 6Taucher S, Rudas M, Gnant M, et al. Sequential steroid hormone receptor measurernents in primary breast cancer with and without intervening primary chemotherapy [J]. Endocr Relat Cancer, 2003,10 (1) : 91-98.
  • 7van de Ven S,Smit VT,Dekker TJ,et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer[J]. Cancer Treat Rev, 2011,37 (6) : 422-430.
  • 8Neubauer H, Gall C, Vogel U, et al. Changes in tumour biolo- gical markers during primary systemic chemotherapy (PSI') [J]. Anticancer Res, 2008,28 (3B) : 1797-1804.
  • 9Kasamin,Uematsut,Honda M. Comparison of estrogen receptor,progesterone receptor and Her-2 status in breast cancer pre-and post-neoadjuvant chemotherapy[J].{H}BREAST,2008,(5):523-527.
  • 10Taucher S,Rudas M,Gnant M. Sequentialsteroid hom one receptor measurements in primary breast cancer with and without intervening primary chemotherapy[J].{H}Endocrine Related Cancer,2003,(1):91-98.

引证文献3

广东医学
2010年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部